The CheckMate 511 phase IIIb/IV trial investigated raising the nivolumab dose to 3 mg/kg and lowering the ipilimumab dose to 1 mg/kg.
Christina Bennett, MS
The US Food and Drug Administration explored the possibility of such bias in a recent viewpoint published in JAMA Oncology.
The latest trial results are based on a larger patient population and were reported at the 2019 ASCO Genitourinary Cancers Symposium.
The results of the double-blind, phase III trial were presented at the 2019 ASCO Genitourinary Cancers Symposium.
Researchers identified two germline pathogenic variants in CHEK2 that may account for a minority of men diagnosed with testicular germ cell tumors.
An exploratory analysis showed that patients who received nivolumab plus ipilimumab had better patient-reported outcomes. Do the results hold up?
Results of the 2-year follow-up analysis of the pivotal KEYNOTE-024 trial were recently published in the Journal of Clinical Oncology.
The study, published in JAMA Oncology, examined whether treatment of 22 solid tumor types was associated with two therapy-related conditions.
An analysis of a large, phase III trial investigated a potential surrogate endpoint for survival outcomes in prostate cancer patients receiving ADT.
The results of the study add to the growing body of literature regarding potential biomarkers for response to immune checkpoint inhibitors.